Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$4.94 - $7.69 $345,800 - $538,300
-70,000 Closed
0 $0
Q3 2021

Nov 17, 2021

BUY
$5.3 - $7.89 $371,000 - $552,300
70,000 New
70,000 $371,000
Q1 2021

May 06, 2021

SELL
$6.93 - $9.63 $2.77 Million - $3.85 Million
-400,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$4.28 - $7.87 $1.71 Million - $3.15 Million
400,000 New
400,000 $3.06 Million

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $48.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.